AQR Capital Management LLC Acquires 695,227 Shares of 10x Genomics $TXG

Key Points

• AQR Capital Management LLC significantly increased its stake in 10x Genomics by 134.4%, owning approximately 0.99% of the company, valuing their shares at $10.6 million.
• In recent transactions, insider Benjamin J. Hindson sold 7,486 shares while CFO Adam Taich sold 22,315 shares, indicating a decrease in their positions.
• Analyst ratings for 10x Genomics are predominantly positive, with multiple analysts assigning an "overweight" rating and average price targets ranging from $14.00 to $16.00 per share.

AQR Capital Management LLC grew its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 134.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,212,429 shares of the company's stock after purchasing an additional 695,227 shares during the quarter. AQR Capital Management LLC owned about 0.99% of 10x Genomics worth $10,585,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Amundi increased its holdings in 10x Genomics by 16,013.7% in the first quarter. Amundi now owns 320,340 shares of the company's stock worth $2,553,000 after purchasing an additional 318,352 shares in the last quarter. Perbak Capital Partners LLP acquired a new stake in shares of 10x Genomics during the 1st quarter worth approximately $306,000. PDT Partners LLC increased its stake in shares of 10x Genomics by 85.7% in the 1st quarter. PDT Partners LLC now owns 659,040 shares of the company's stock valued at $5,753,000 after acquiring an additional 304,082 shares in the last quarter. Royal Bank of Canada lifted its position in shares of 10x Genomics by 806.4% during the 1st quarter. Royal Bank of Canada now owns 182,836 shares of the company's stock valued at $1,597,000 after acquiring an additional 162,665 shares during the period. Finally, Quarry LP bought a new position in 10x Genomics during the first quarter worth $78,000. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Stock Performance

TXG stock traded down $0.22 during mid-day trading on Tuesday, hitting $13.13. The company had a trading volume of 3,114,345 shares, compared to its average volume of 2,167,905. The firm has a market cap of $1.63 billion, a PE ratio of -18.76 and a beta of 2.00. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.38. The stock's fifty day moving average price is $13.26 and its two-hundred day moving average price is $10.84.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TXG shares. UBS Group lifted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 target price on 10x Genomics and gave the company a "hold" rating in a research note on Friday, August 8th. Bank of America upped their price target on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Thursday, June 26th. Morgan Stanley reduced their price objective on 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Finally, Zacks Research lowered 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Six analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $13.65.

Insiders Place Their Bets

In other news, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This represents a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company's stock, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 over the last ninety days. 10.03% of the stock is currently owned by insiders.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.